Renovo’s mission is to provide high-quality preclinical contract research services specializing in neuroscience. Renovo’s core expertise includes preclinical efficacy testing for neurodegenerative diseases, neurohistology services and electron microscopy imaging and analysis.  Renovo strives to provide high quality research services to clients, including biotech and pharmaceutical companies, research organizations and academic researchers by complementing their in-house capabilities. Currently Renovo provides a comprehensive package for early stage drug development of Multiple Sclerosis therapies and continues to develop niche services to build its portfolio to serve other neural disease areas.

Renovo’s core scientific strength and expertise supports reliable and reproducible preclinical assays/models. Renovo provides services on a strictly fee-for-service basis and does not take any intellectual property rights on the work performed for its clients. A comprehensive report is submitted to clients at the end of each project.

Renovo was established in 2008 based on the technology developed in the laboratories of Dr. Bruce Trapp and Dr. Wendy Macklin at the Cleveland Clinic. A strong team of research scientists (consisting of PhD, MS and Bachelor degrees) trained in neuroscience form the core of Renovo’s technical expertise. Renovo operates in a state-of-the-art laboratory with access to nearby Cleveland Clinic Foundation facilities and infrastructure.